Table 36GRADE profiles – amitriptyline vs topical capsaicin as monotherapy

No. of studiesDesignAmi
(T1)
T.Cap
(T2)
Relative risk (95% CI)
[ARI]
[NNTH, 95% CI]
LimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
PRIMARY OUTCOME: Sedation (adverse effects)
1
(PDN1)
RCT69/117
(59.0%)
0/118
(0.0%)
∞ (∞)
ARI = 59.0%
NNTH = N/A
NNNVSaNVery low
PRIMARY OUTCOME: Burning (adverse effects)
1
(PDN1)
RCT0/117
(0.0%)
68/118
(57.6%)
0.00 (0.00, ∞)
ARI = −57.6%
NNTH = N/A
NNNVSaNVery low

Relative risks were calculated in the direction of T1 compared with T2.

T1 = treatment 1; T2 = treatment 2; N = No serious; S = Serious; VS = Very serious

Ami = amitriptyline; T.Cap = topical capsaicin; PDN = painful diabetic neuropathy; N/A = not applicable.

a

GDG consensus: if there is only 1 study with total number of adverse effects less than 100, the GDG decided that the quality should be graded as ‘very low’.

1

From: 2, How this guideline was developed

Cover of Neuropathic Pain
Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings.
NICE Clinical Guidelines, No. 96.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.